We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more

Link to third party site

The link you have selected will take you away from this site to one that is not owned or controlled by Roche, F. Hoffmann-La Roche Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Roche does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

364 Search Results

Emicizumab prophylaxis to facilitate anticoagulant therapy for management of intra‐atrial thrombosis in severe haemophilia with an inhibitor.

Weyand AC, Dorfman AL, Shavit JA and Pipe SW. Haemophilia 2019;25:e203–e205.    

Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes

Camelo RM, de Medeiros TC, de Albuquerque DGB, Álvares-Teodoro J. [published online ahead of print May 7] Hematol Transfus Cell Ther. 2021 May 7:S2531-1379(21)00051-1. doi: 10.1016/j.htct.2021.02.010

Laboratory testing in hemophilia: impact of factor and non-factor replacement therapy on coagulation assays.

Peyvandi F, Kenet G, Pekrul I, et al. J Thromb Haemost 2020;18:1242–1255.

Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.

Yada K, Nogami K, Shinozawa K, et al. Br J Haematol 2018;183:257–266.

Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors

Okamoto S, Suzuki N, Suzuki A, et al. TH Open. 2019;3(4):e364-e366.

Emicizumab use in major orthopedic surgery

Seaman CD, Ragni MV. Blood Adv. 2019;3(11):1722-1724.

Consecutive complex percutaneous coronary interventions using emicizumab and recombinant activated factor VII in a patient with severe haemophilia A and high-titre inhibitor

Chen YW, Chen WJ, Tseng MS, et al. Haemophilia. 2021 May;27(3):e385-e388

Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres

Stonebraker JS, Ducore JM. Haemophilia. 2021 Jan;27(1):e22-e29.

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro

Noguchi-Sasaki M, Soeda T, Ueyama A, et al. TH Open. 2018;2(1):e96-e103.